

Map of Collaborators

The OHDSI community brings together volunteers from around the world to establish open community data standards, develop open-source software, conduct methodological research, and apply scientific best practices to both answer public health questions and generate reliable clinical evidence.

Our community is ALWAYS seeking new collaborators. Do you want to focus on data standards or methodological research? Are you passionate about open-source development or clinical applications? Do you have data that you want to be part of global network studies? Do you want to be part of a global community that truly values the benefits of open science? Add a dot to the map below and JOIN THE JOURNEY!

OHDSI By The Numbers

- 2,367 collaborators
- 74 countries
- 21 time zones
- 6 continents
- 1 community





EHDEN: VISION AND MISSION



Vision

The European Health Data & Evidence Network (EHDEN) aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes and care

Mission

Our mission is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardized to a common data model



EHDEN CONSORTIUM



Start date: 1 Nov 2018

End date: 30 Apr 2024

Duration: 66 months




22 partners



Almost €29 million

Universities, public bodies and research organisations



SME & Mid-sized companies



Non-profit organisations



EFPIA & Associated partners




EFPIA Lead






EHDEN IS ABOUT...





AFTER TWO CALLS EHDEN HAS CERTIFIED 26 SMEs IN 14 COUNTRIES


Adding 23 SMEs in 2021!



Certified SMEs (n=26)




Applications (n=63)






AFTER FOUR CALLS WE SELECTED 98 DATA PARTNERS IN 22 COUNTRIES




Geographic spread of data partners. The shade of blue indicates the # of data partners in that country (darker = more)






THE EHDEN FEDERATED DATA NETWORK






LARGE-SCALE OBSERVATIONAL RESEARCH IS FEASIBLE


T2 Diabetes Mellitus



Hypertension



Depression



11 Data sources



4 Countries



> 250 million patients

"Characterizing treatment pathways at scale using the OHDSI network."

George Hripcsak et al. - PNAS (2016)27:7329–7336



EHDEN HAS CONTRIBUTED TO 36 PUBLICATIONS IN ITS FIRST YEARS*

The screenshot shows the Zenodo website interface. At the top, there's a blue header with the Zenodo logo, a search bar containing "European Health D", and links for "Upload" and "Communities". On the right of the header are "Log in" and "Sign up" buttons. Below the header, the page title "European Health Data and Evidence Network" is displayed. The main content area shows search results for "All versions". On the left, there are filters for "Access Right" (Open: 55), "File Type" (PDF: 63, Zip: 2), and "Keywords" (COVID-19: 20, OMOP: 14, Common Data Model: 6, Demographics: 5, Electronic Health Records: 5, Hydroxychloroquine: 5, COVID-19: 4, Characterisation: 4, Safety: 4, Academy: 3). The search results show 36 results. The first result is dated June 5, 2021, titled "Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study". The second result is dated April 16, 2021, titled "Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study".

zenodo Search European Health D [q] Upload Communities Log in Sign up

European Health Data and Evidence Network

All versions

Access Right

☐ Open (55)

File Type

☐ PDF (63)

☐ Zip (2)

Keywords

☐ COVID-19 (20)

☐ OMOP (14)

☐ Common Data Model (6)

☐ Demographics (5)

☐ Electronic Health Records (5)

☐ Hydroxychloroquine (5)

☐ COVID-19 (4)

☐ Characterisation (4)

☐ Safety (4)

☐ Academy (3)

Found 36 results:

Sort by: Most recent asc View

June 5, 2021 (v1) Journal article Open Access

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study

Xintong Li, Anna Ostropolets, Rupa Makadiy, Azza Shoult, Gowtham Rao, Anthony G Sena, Eugenia Martinez-Hernandez, Antonella Delmestri, Kasia Veihamme, Peter R Rijnbeek, Talita Duarte-Galles, Marc A Suchard, Patrick D Ryan, George Hripcoak, Daniel Prieto-Alhambra

Objective - To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. Design - Multinational network cohort study. Setting - Electronic health records and health claims data from eight countries: Australia, France, G

Updated on June 14, 2021

Published in the BMJ

April 16, 2021 (v1) Journal article Open Access

Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study

Albert Prats-Uribar, Anthony G Sena, Lana Yin Hui Lai, Waheed-Ul-Rahman Ahmed, Heba Alghout, Ossaid Alser, Thamir M Alshammari, Carlos Areia, William Carter, Paula Casajust, Dalia Dawoud, Asieh Golozar, Jitendra Jonnagaddala, Paras P Mehta, Mengchun Gong, Daniel R Morales, Fredrik Nyberg, Jose D Posada, Martina Recalde, Elena Roel, Karishma Shah, Nigam H Shah, Lisa M Schilling, Vignesh Subolan, David Vazaya, Lin Zhang, Ying Zhang, Hong Zhu, Li Liu, Jaehyeon Choi, Kristine E Lynch, Michael E Matherly, Seng Chan You, Peter R Rijnbeek, George Hripcoak, Jennifer OE Lane, Edward Burn, Christian Reich, Marc A Suchard, Talita Duarte-Galles, Kristin Koska, Patrick D Ryan, Daniel Prieto-Alhambra

Objective - To investigate the use of repurposed and adjuvant drugs in patients admitted to hospital with covid-19 across three continents. Design - Multinational network cohort study. Setting - Hospital electronic health records from the United States, Spain, and China, and nationwide claims data



Updated on May 19, 2021

Published in BMJ, vol. 373, issue n1035



*including pre-prints

Clinical Pharmacology & Therapeutics

Perspective |  Open Access |   

Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value

Peter Arlett , Jesper Kjær, Karl Broich, Emer Cooke

First published: 19 November 2021 | <https://doi.org/10.1002/cpt.2479>



EHDEN PART OF EMA COVID-19 STRATEGY



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Medicines ▾ Human regulatory ▾ Veterinary regulatory ▾ Committees ▾ News & events ▾ Partners & networks ▾

COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines [◀ Share](#)

News 21/07/2020

In June, EMA contracted the company IQVIA with a project to build a framework for the conduct of **multicentre cohort studies on the use of medicines in COVID-19 patients**. This project will include the identification of large national cohorts of COVID-19 patients and appropriate comparator groups, the development of a study protocol template for multinational studies as well as the establishment of a collaborative framework for researchers. The project will be carried out in collaboration with the [European Health Data & Evidence Network \(EHDEN\)](#) [↗](#) consortium, which was established under the [Innovative Medicines Initiative](#) [↗](#) and includes the Erasmus Medical Centre in Rotterdam and the University of Oxford as project lead and research coordinator, respectively.*

Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU



News 09/02/2022

EMA is initiating today the establishment of the Coordination Centre for the [Data Analysis and Real World Interrogation Network \(DARWIN EU®\)](#).

The role of the Coordination Centre is to develop and manage a network of real-world healthcare data sources across the EU and to conduct scientific studies requested by medicines regulators and, at a later stage, requested by other stakeholders.

The vision of DARWIN EU® is to give EMA and national competent authorities in EU Member States access to valid and trustworthy real-world evidence, for example on diseases, patient populations, and the use, safety and effectiveness of medicines, including vaccines, throughout the lifecycle of a medicinal product.


By supporting decision-making on the development, authorisation and surveillance of medicines, a wide range of stakeholders will benefit, from patients and healthcare professionals to health technology assessment bodies and the pharmaceutical industry. Additionally, DARWIN EU® will provide an invaluable resource to prepare for and respond to future healthcare crises and pandemics.



EHDEN IS AN EVOLVING EUROPEAN LANDSCAPE: EUROPEAN HEALTH DATA SPACE



- The EHDS will be a federated network akin to the structure of the internet
- Multiple nodes from data to permit authorities within a resilient international framework
- Interoperability via standards, systems and governance for cross-border networking
- Attitudinal change on the role of data for research





WHAT'S IN IT FOR DATA PARTNERS?



- Financial support
- Scientific collaboration
- Scientific independence
- Pioneering the future of healthcare
- Improved interoperability
- Increased visibility, e.g. publications
- Larger academic impact
- Transparency & reproducibility
- Increased analytic capabilities
- EHDEN Academy
- Faster performing studies
- 21st century evidence generation
- Real world evidence framework
- Support own decision-making processes



KEY CONTACT POINTS

- EHDEN Coordinator: Assoc Prof Peter Rijnbeek, Erasmus Medical Centre: p.rijnbeek@erasmusmc.nl
- EHDEN Coordinator: Nigel Hughes, Janssen: nhughes@its.inj.com



EHDEN
EUROPEAN HEALTH DATA & EVIDENCE NETWORK

<https://forum.ehden.eu>



enquiries@ehden.eu



www.ehden.eu



[@IMI_EHDEN](https://twitter.com/IMI_EHDEN)



[IMI_EHDEN](https://www.linkedin.com/company/IMI_EHDEN)



github.com/EHDEN



innovative
medicines
initiative



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.